← Leaderboards
Jung-Mo Ahn
University Of Texas Dallas
$1,216,996
Attributed
$2,786,993
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $722K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,786,993 · 3
By mechanism
R01$2,102,493 · 1
R41$455,000 · 1
R56$229,500 · 1
Top collaborators
- Ratna K Vadlamudi4 shared
- Jer-Tsong Hsieh2 shared
- Zhi-Ping Liu2 shared
- Ganesh V Raj2 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsPathway InteractionsIn VivoAnalogResponseXenograft ModelXenograft ProcedureCell LineMolecularNovel TherapeuticsProteinsResistanceSignal PathwayTumorEfficacy TestingIn VitroCancer PatientGrowthDrug KineticsLead OptimizationPharmacodynamicsBiologicalPrognosisBase
Grant awards (7)
Enhancing endoplasmic reticulum stress in ovarian cancer$526,459
R01 · FY2025 · CA
Enhancing endoplasmic reticulum stress in ovarian cancer$283,533
R01 · FY2024 · CA
Enhancing endoplasmic reticulum stress in ovarian cancer$625,549
R01 · FY2023 · CA
Enhancing endoplasmic reticulum stress in ovarian cancer$666,952
R01 · FY2022 · CA
Development of small molecule epigenetic therapeutics for prostate cancer$55,000
R41 · FY2022 · CA
Development of small molecule epigenetic therapeutics for prostate cancer$400,000
R41 · FY2021 · CA
Rational Design of Peptidomimetics Targeting Glucagon-Like Peptide-1 Receptors$229,500
R56 · FY2010 · DK · contact PI